TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs

Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) is one of the best biotech penny stocks to buy according to analysts. On December 10, TD Cowen analyst Joshua Jennings initiated coverage of Orchestra BioMed with a Buy rating and $15 price target. TD Cowen believes that Orchestra BioMed is at the leading edge of cardiovascular device innovation. Its royalty-based model is anchored by two key programs: AVIM for hypertension and Virtue SAB for atherosclerotic disease, both of which target massive market gaps. With blue-chip partners and high-margin potential, the company is approaching critical data and commercialization milestones that could prove transformative.

The company is currently advancing two high-impact pivotal programs. Enrollment officially initiated for the Virtue Trial as of Q3 2025, which is a US registrational study comparing Virtue SAB head-to-head against the commercially available AGENT paclitaxel-coated balloon for treating coronary in-stent restenosis. Orchestra BioMed Holdings Inc. remains in full operational control of this trial, with enrollment completion targeted for mid-2027. Simultaneously, the company is progressing its BACKBEAT global pivotal study for Atrioventricular Interval Modulation/AVIM Therapy. Recent FDA-approved protocol enhancements have expanded the enrollment criteria for BACKBEAT, increasing the eligible patient pool more than 24-fold, with enrollment completion expected in mid-2026.

TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs

Orchestra BioMed Holdings Inc. (NASDAQ:OBIO recently expanded its partnership with Medtronic, establishing a development pathway for AVIM Therapy-enabled leadless pacemakers. While Terumo holds a ROFR for certain transactions, Orchestra BioMed retains all development and distribution rights for Virtue SAB across all indications.

Orchestra BioMed Holdings Inc. operates as a biomedical company in the US. It collaborates with Medtronic for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients, and with Terumo Corporation and Terumo Medical Corporation for developing and commercializing Virtue SAB for the treatment of coronary and peripheral artery disease.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.